FDA recent expectations on generic product development: A comprehensive review

Abstract

The United States Food and Drug Administration (FDA) has significantly evolved its regulatory framework for generic drug development over recent years, introducing new guidance documents, streamlined pathways, and enhanced scientific standards. This review examines the FDA’s current expectations for generic product development, focusing on bioequivalence requirements, complex generic formulations, quality standards, and emerging regulatory pathways. Key developments include the expansion of alternative bioequivalence approaches, enhanced guidance for complex products, implementation of the Generic Drug User Fee Amendments (GDUFA III), and increased focus on pharmaceutical quality metrics. This article provides a comprehensive analysis of these developments and their implications for generic drug manufacturers navigating the current regulatory landscape.

Keywords

Generic product development office of generic drugs bioequivalence biopharmaceutics classification system international council for harmonisation (ICH)

Get full access to this article

View all access options for this article.

References

Association for Accessible Medicines . 2024 Generic drug & biosimilars access and savings in the U.S. report. AAM, 2024.

FDA. Generic Drug User Fee Amendments Reauthorization (GDUFA III) . Commitment letter. FDA, 2022.

Federal Register . Generic drug user fee amendments of 2022. Fed Regist 2022; 87(198): 62451–62489.

FDA . Guidance for industry: bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA, 2021.

FDA . Guidance for industry: assessing the effects of food on drugs in INDs and NDAs — clinical pharmacology considerations. FDA, 2022.

FDA . Draft guidance: population pharmacokinetics. FDA, 2020.

Zhang

Yang

Grimstein

, et al. Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018-2019 submissions. J Clin Pharmacol 2020; 60: S160–S178. https://doi.org/10.1002/jcph.1767

FDA . Guidance for industry: locally acting drug products: quality, efficacy, and safety considerations. FDA, 2023.

ICH . M13A: bioequivalence for immediate-release solid oral dosage forms. ICH, 2024.

10.

Lionberger

Raw

Kim

, et al. Alternative bioequivalence approaches for complex generic drug products. Clin Pharmacol Ther 2023; 113(4): 758–767.

11.

FDA . Draft guidance: bioequivalence recommendations for specific orally inhaled drug products. FDA, 2023.

12.

Newman

Chan

. In Vitro–In vivo correlations for drugs delivered by inhalation. Pharm Res 2023; 40: 2615–2629.

13.

Zhao

Kim

Zhang

, et al. Quantitative analyses of physiologically based pharmacokinetic model submission to support regulatory decision making. Clin Pharmacol Ther 2023; 114(1): 98–106.

14.

FDA . Guidance for industry: the use of physiologically based pharmacokinetic analyses — biopharmaceutics applications for oral drug product development. FDA, 2023.

15.

Heimbach

Kesisoglou

Novakovic

, et al. PBPK modeling to support waivers of in vivo clinical studies. Pharm Res 2023; 40: 1833–1851.

16.

FDA . Manual of policies and procedures: MAPP 5240.3 Rev.3 prioritization of the review of ANDAs. FDA, 2022.

17.

FDA . Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin. FDA, 2021.

18.

Burgess

Crommelin

DJA

Hussain

, et al. Assuring quality and performance of complex parenteral products. AAPS J 2024; 26: 15.

19.

Martinez

Mochel

Neuhoff

, et al. Physiologically based pharmacokinetic modeling for drug development and regulatory science. J Pharm Sci 2023; 112(1): 32–43.

20.

FDA . Guidance for industry: comparative analyses and related comparative use human factors studies for drug-device combination products. FDA, 2022.

21.

FDA . Product-specific guidances for generic drug development database. Available at: https://www.accessdata.fda.gov/scripts/cder/psg/ (accessed January 2025).

22.

FDA. Guidance for industry: physicochemical and structural characterization of synthetic peptides. FDA; 2021.

23.

Berkowitz

Engen

Mazzeo

, et al. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov 2023; 22: 483–500.

24.

FDA . Draft guidance: drug products, including biological products, that contain nanomaterials. FDA, 2022.

25.

Zheng

Sun

Zou

, et al. Scientific and regulatory considerations for generic complex drug products. Drug Discov Today 2023; 28: 103518.

26.

FDA . Guidance for industry: Control of nitrosamine impurities in human drugs. FDA, 2023.

27.

Schlingemann

Burns

Ponting

, et al. The landscape of potential small and drug substance related nitrosamines in pharmaceuticals. J Pharm Sci 2023; 112: 1287–1304. https://doi.org/10.1016/j.xphs.2022.11.013

28.

FDA . Updates on possible mitigation strategies to reduce the risk of nitrosamine drug substance-related impurities. FDA, 2023.

29.

Boetzel

Bellamy

Cross

, et al. A nitrite excipient database for evaluation of N-Nitrosamine risk. J Pharm Sci 2023; 112: 1615–1624.

30.

FDA. Liquid Chromatography-High . Resolution mass spectrometry method for determination of nitrosamine impurities. FDA, 2023.

31.

Cioc

Joyce

Dong

. Recent advances in the analytical determination of N-Nitrosamines in pharmaceutical products. J Pharm Biomed Anal 2023; 234: 115522.

32.

FDA . Inactive ingredient database. Available at: https://www.accessdata.fda.gov/scripts/cder/iig/ (accessed January 2025).

33.

FDA . Orange book: approved drug products with therapeutic equivalence evaluations. Available at: https://www.accessdata.fda.gov/scripts/cder/ob/ (accessed January 2025).

34.

FDA . Guidance for industry: general clinical pharmacology considerations for pediatric studies of drugs. FDA, 2022.

35.

FDA . Manual of policies and procedures: MAPP 5210.8 review and update of product-specific guidances. FDA, 2023.

36.

Raw

, et al. FDA's new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications. Int J Pharm 2024; X6: 100205.

37.

Federal Register . Requests for comments on product-specific guidances. Fed Regist 2023; 88(147): 51234–51237.

38.

FDA . Guidance for industry: formal meetings between FDA and ANDA applicants of complex products under GDUFA. FDA, 2023.

39.

FDA . GDUFA III enhanced communication pathways. FDA, 2023.

40.

FDA . Best practices for communication between FDA and ANDA applicants. FDA, 2023.

41.

ICH. Q3D(R2): guideline for elemental impurities. ICH; 2022.

42.

FDA . Guidance for industry: elemental impurities in drug products. FDA, 2023.

43.

Barin

Talley

Flanagan

, et al. Implementation of ICH Q3D elemental impurities guideline: challenges and opportunities. Pharm Res 2023; 40: 1447–1461.

44.

FDA . Questions and answers on implementation of ICH Q3D. FDA, 2023.

45.

Jenke

Odufu

Poss

, et al. Safety risk categorization of extractable and leachable impurities. PDA J Pharm Sci Technol 2023; 77: 225–242.

46.

FDA . Draft guidance: submission of quality metrics data. FDA, 2022.

47.

FDA . Report on the state of pharmaceutical quality. FDA, 2023.

48.

Friedli

Nasr

, et al. Pharmaceutical quality metrics: practical implementation. Pharm Eng 2023; 43: 46–55.

49.

FDA . Quality metrics site visit program for human drug manufacturing facilities. FDA, 2023.

50.

FDA . Guidance for industry: continuous manufacturing considerations for ANDAs. FDA, 2023.

51.

Lee

O'Connor

Yang

, et al. Modernizing pharmaceutical manufacturing: from batch to continuous production. J Pharm Innov 2023; 18: 872–890.

52.

Vanhoorne

Vervaet

. Recent progress in continuous manufacturing of solid oral dosage forms. Int J Pharm 2023; 643: 123213.

53.

FDA . Guidance for industry: changes to an approved application for specified biotechnology and synthetic biological products. FDA, 2023.

54.

FDA . Guidance for industry: comparability protocols for postapproval changes to the chemistry, manufacturing, and controls information in an ANDA. FDA, 2022.

55.

FDA . Guidance for industry: human factors studies and related clinical study considerations in combination product design and development. FDA, 2023.

56.

Privitera

Welty

Gidal

, et al. Generic-to-Generic lamotrigine switches in people with epilepsy. Lancet Neurol 2023; 22: 585–598.

57.

FDA . Guidance for industry: statistical approaches to establishing bioequivalence. FDA, 2022.

58.

FDA . Guidance for industry: pediatric study plans: content of and process for submitting initial pediatric study plans and amended initial pediatric study plans. FDA, 2023.

59.

Salunke

Tuleu

. Formulating better pediatric medicines. Int J Pharm 2023; 642: 123152.

60.

FDA . FDA's global engagement report. FDA, 2023.

61.

ICH . M13A: bioequivalence for immediate-release solid oral dosage forms. ICH, 2024.

62.

ICH . Q13: continuous manufacturing of drug substances and drug products. ICH, 2023.

63.

ICH . Q12: technical and regulatory considerations for pharmaceutical product lifecycle management. ICH, 2023.

64.

FDA . Mutual recognition agreement between FDA and European Union. FDA, 2023.

65.

FDA . Drug establishments current registration site database. FDA, 2024.

66.

FDA . Digital health software precertification program. FDA, 2023.

67.

FDA . Guidance for industry: cybersecurity in medical devices. FDA, 2023.

68.

FDA . Advanced manufacturing technologies designation program. FDA, 2023.

69.

Rantanen

Khinast

. The future of pharmaceutical manufacturing sciences. J Pharm Sci 2023; 112: 2990–3000.

70.

FDA . GDUFA science and research report FY2023. FDA, 2023.

71.

Raw

Lionberger

. Pharmaceutical equivalence by design for generic drugs: modified-release products. Pharm Res 2023; 40: 1481–1491.

72.

FDA . Guidance documents database. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents (accessed January 2025).

73.

FDA . Manual of policies and procedures. FDA, 2024.

74.

FDA . CDER small business and industry assistance. Available at: https://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia (accessed January 2025).

75.

FDA . Advisory committees. Available at: https://www.fda.gov/advisory-committees (accessed January 2025).

76.

FDA . Electronic submissions gateway. FDA, 2024.

77.

FDA . Data standards resources. FDA, 2024.

78.

FDA . Guidance for industry: Q8(R2) pharmaceutical development. FDA, 2023.

79.

Amidon

Khan

, et al. Understanding pharmaceutical quality by design. AAPS J 2023; 25: 7.

80.

Rathore

Winkle

. Quality by design for biopharmaceuticals: principles and case studies. Nat Biotechnol 2023; 41: 21–32.

81.

FDA . Pharmaceutical quality/chemistry manufacturing and controls (PQ/CMC). FDA, 2023.

82.

FDA . Strategic plan for regulatory science. FDA, 2023.

83.

Meyer

Zanger

Schwab

. Pharmacogenomics: from bench to byte. Nat Rev Drug Discov 2023; 22: 879–896.

84.

FDA . Guidance for industry: clinical pharmacogenomics: premarket evaluation in early-phase clinical studies. FDA, 2023.

85.

FDA . Environmental assessment of human drug and biologics applications. FDA, 2023.

86.

Anastas

Zimmerman

. The molecular basis of green chemistry. Science 2023; 382: 1185–1189.

87.

FDA . Framework for FDA's real-world evidence program. FDA, 2023.

88.

Sherman

Anderson

Dal Pan

, et al.

Real-world evidence — what is it and what can it tell us?

N Engl J Med 2023; 389: 2293–2297. https://doi.org/10.1056/NEJMsb1609216

89.

Woodcock

Wosinska

. Economic and technological drivers of generic sterile injectable drug shortages. Clin Pharmacol Ther 2023; 113: 246–250.

90.

FDA . Annual report on drug shortages for calendar year 2023. FDA, 2024.

91.

FDA . Patient-focused drug development guidance series. FDA, 2023.

92.

FDA . Benefit-risk assessment for new drug and biological products. FDA, 2023.

93.

FDA . Advancing regulatory science initiative. FDA, 2024.

94.

FDA . Generic drugs: Questions & answers. Available at: https://www.fda.gov/drugs/generic-drugs/questions-answers (accessed January 2025).